CGON (CG Oncology) Buyback Yield %: -6.31 (As of Jul. 06, 2026)


CGON CG Oncology Inc CGON
12 GF Score
Price $69.27
! 5 Warning Signs
View Full Analysis

What is CG Oncology Buyback Yield %?

CG Oncology CGON -1.56% 12 Buyback Yield % is -6.31 as of Jul. 06, 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 741 Biotechnology companies, CG Oncology ranks better than 56.14% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

CG Oncology's current buyback yield was -6.31%.

CG Oncology Buyback Yield % Historical Data

* Premium members only.

The historical data trend for CG Oncology's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology Buyback Yield % Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00 -28.82 -4.40

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -4.40 -6.57

CGON vs COGT, SRRK, LGND: Buyback Yield % Comparison

For the Biotechnology subindustry, CG Oncology's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where CG Oncology's Buyback Yield % falls into.


CGON
12GF Score
CG Oncology Inc CGON
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

CG Oncology's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 147.45) / 3350.20728
=-4.40%

CG Oncology's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 391.55) / 5956.38144
=-6.57%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -6.31 mean?
CG Oncology (CGON) has a Buyback Yield % of -6.31 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CG Oncology and its competitors. According to the industry distribution chart, CG Oncology ranks #325 out of 741 companies in the Biotechnology industry, placing it in the top 43.9%.
Is CG Oncology's Buyback Yield % too high?
CG Oncology's current Buyback Yield % is -6.31. Based on the distribution chart, CG Oncology ranks #325 out of 741 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Buyback Yield % compare to COGT and SRRK?
According to the Biotechnology industry distribution chart, CG Oncology ranks #325 out of 741 companies for Buyback Yield %. This puts CG Oncology in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on CG Oncology and its competitors. CG Oncology's current Buyback Yield % is -6.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Buyback Yield % of -6.31. The current Buyback Yield % is -6.31. CG Oncology's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For CG Oncology (CGON), the current Buyback Yield % is -6.31 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$69.27
Price